Zydus Lifesciences Announces Rs 1,100 Crore Share Buyback: Key Dates and Details
Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premium
Image: The Economic Times
Zydus Lifesciences is set to conduct a share buyback worth Rs 1,100 crore, with the last date to purchase shares being May 27. The buyback price is fixed at Rs 1,150 per share, representing a 7% premium over the last closing price. Eligible shareholders must own shares by the record date of May 29.
- 01The share buyback will involve up to 95.65 lakh shares, accounting for 0.95% of Zydus Lifesciences' paid-up equity.
- 02The buyback price is set at Rs 1,150 per share, which is a 7% premium from the previous closing price of Rs 1,079.05.
- 03Zydus Lifesciences had previously conducted a Rs 600 crore buyback at Rs 1,005 per share, indicating a trend of returning capital to shareholders.
- 04As of May 15, 2026, promoters held nearly 75% of the company's shares, with retail investors and mutual funds each holding around 5%.
- 05The company reported a consolidated net profit of Rs 1,272.5 crore for Q4 FY26, a 9% increase from the previous year.
Advertisement
In-Article Ad
Zydus Lifesciences has announced a significant share buyback program worth Rs 1,100 crore, with a last purchase date of May 27, 2026. The record date for eligibility to participate in the buyback is set for May 29. The company will buy back up to 95.65 lakh shares at a price of Rs 1,150 each, reflecting a 7% premium over the last closing price of Rs 1,079.05. This initiative follows a previous buyback of Rs 600 crore at Rs 1,005 per share. The board has also formed a buyback committee that can adjust the buyback price or the number of shares up to one day before the record date. As of mid-May 2026, the promoter group holds about 75% of the company's equity, while retail investors and mutual funds own approximately 5% each. Zydus Lifesciences reported a consolidated net profit of Rs 1,272.5 crore for the January-March quarter, marking a 9% increase year-on-year, alongside a revenue increase of over 16%.
Advertisement
In-Article Ad
The buyback program may influence share prices and investor sentiment positively, potentially benefiting current shareholders.
Advertisement
In-Article Ad
Reader Poll
Are you planning to participate in Zydus Lifesciences' share buyback?
Connecting to poll...
Read the original article
Visit the source for the complete story.